CLINUVEL PHARMACEUTICALS LIMITED

0.27%

$11.01

Market Cap $551.8M

Healthcare Biotechnology

Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical... Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Latest Threads

Tag

Subject

CUV

Ann: Notification regarding unquoted securities - CUV

25/04/25

2.0K

25/04/25

Last post ChrizzlyAdams

2.0K

CUV

Yahoo Zoo

25/04/25

1.6K

25/04/25

Last post rpape1

1.6K

CUV

Clinuvel and Nanosonics

23/04/25

11K

23/04/25

Last post mondyinvest

11K

CUV

Don't mind us Clinuvel...

22/04/25

703

22/04/25

Last post SilentPartnr

703

CUV

Pringle speaks

16/04/25

4.4K

16/04/25

Last post spanfred

4.4K

CUV

All the world's a stage

16/04/25

6.8K

16/04/25

Last post rpape1

6.8K

CUV

Renewed SHare Buy Back

15/04/25

9.1K

15/04/25

Last post Melon felon!

9.1K

CUV

Clinuvel Takeover

13/04/25

15K

13/04/25

Last post cuv101

15K

See All Discussions

Timeline

Notification regarding unquoted securities - CUV
23 Apr 09:00	Share

Notification of cessation of securities - CUV
09 Apr 08:22	Share

Section 708A Cleansing Statement
07 Apr 08:55	Share

Application for quotation of securities - CUV
07 Apr 08:51	Share

Application for quotation of securities - CUV
07 Apr 08:49	Share

Change in substantial holding
01 Apr 19:43	Share

Notification of buy-back - CUV
27 Mar 09:04	Share

CLINUVEL renews share buy-back program
27 Mar 09:03	Share

Update - Notification of buy-back - CUV
27 Mar 08:58	Share

Positive preliminary results for PRENUMBRA Instant in stroke
26 Mar 09:15	Share

2025 American Academy of Dermatology Annual Meeting
24 Mar 09:19	Share

CLINUVEL management update
18 Mar 09:02	Share

CLINUVEL Unveils Vitiligo Program for AAD 2025
04 Mar 08:59	Share

CLINUVEL Investor Webinar
28 Feb 09:06	Share

Chair Letter to Shareholders
28 Feb 09:04	Share

Half Year Results Presentation
27 Feb 10:48	Share

Half Year Results Announcement
27 Feb 10:47	Share

Appendix 4D and Half Year Report
27 Feb 10:42	Share

CLINUVEL Investor Webinar
20 Feb 09:05	Share

Change in substantial holding
17 Feb 08:20	Share

Preliminary results from SCENESSE adolescent EPP study
10 Feb 09:05	Share

Vitiligo - CUV105 Study Update
20 Jan 09:39	Share

SCENESSE Argentinian distribution agreement
17 Jan 09:22	Share

Managing Director Letter to Shareholders
23 Dec 09:18	Share

Health Canada validates SCENESSE New Drug Submission
23 Dec 09:16	Share

Revised Securities Trading Policy
18 Dec 16:11	Share

Becoming a substantial holder
06 Dec 08:21	Share

Chair's letter to Shareholders
05 Dec 09:06	Share

Notification of cessation of securities - CUV
04 Dec 09:19	Share

SCENESSE dosage expansion under review by EMA
20 Nov 09:13	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $11.01		Change -0.030(0.27%)		Mkt cap ! $551.8M

Open	High	Low	Value	Volume
$11.07	$11.20	$10.81	$613.6K	55.75K

Buyers (Bids)

No.	Vol.	Price($)
1	250	$10.93

Sellers (Offers)

Price($)	Vol.	No.
$11.08	160	1

View Market Depth

No.	Vol.	Price($)
1	250	10.930
1	500	10.900
1	92	10.850
2	3768	10.810
1	1000	10.700

Price($)	Vol.	No.
11.080	160	1
11.240	1000	1
11.290	500	1
11.410	500	1
11.630	5000	1

Last trade - 16.10pm 25/04/2025 (20 minute delay)

CUV (ASX) Chart

CLINUVEL PHARMACEUTICALS LIMITED

Corporate Spotlight
Not Yet Available

Latest Threads

Timeline

Featured News

Latest Articles

Clinuvel stroke drug shows 'positive' results – but some adverse effects left unclear

Clinuvel shares jumped on Tuesday on higher volumes as the company reported a clinical trial win with its stroke drug, 'PRENUMBRA.'

British study shows Clinuvel drug effective on DNA of UV-damaged skin

Clinuvel Pharmaceuticals Ltd has reported final results of its study of the efficacy of afamelanotide to repair the DNA of damaged skin.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News

CLINUVEL PHARMACEUTICALS LIMITED

Corporate SpotlightNot Yet Available

Latest Threads

Timeline

Featured News

Latest Articles

Clinuvel stroke drug shows 'positive' results – but some adverse effects left unclear

Clinuvel shares jumped on Tuesday on higher volumes as the company reported a clinical trial win with its stroke drug, 'PRENUMBRA.'

British study shows Clinuvel drug effective on DNA of UV-damaged skin

Clinuvel Pharmaceuticals Ltd has reported final results of its study of the efficacy of afamelanotide to repair the DNA of damaged skin.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News

Corporate Spotlight
Not Yet Available